Buying guide
mBos TKA System vs Mako in 2026
Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.
Key differences
- Mako has more verified real-world deployments (2 vs 1).
- mBos TKA System is at the research stage; Mako at the commercial stage.
| Attribute | No image on file | |
|---|---|---|
| Manufacturer | Monogram Technologies | Stryker |
| Form factor | surgical | surgical |
| Maturity | research | commercial |
| Autonomy | — | ◐ not independently verified |
| Availability | internal-onlyenterprise | internal-onlyenterprise |
| Price | Not announced | $1,000,000-$1,500,000 (actual sale price) |
| Capability claims | — |
|
| Brain | — | — |
| Verified deployments | 1Ahmedabad | 2United Kingdom, United States |
| Privacy practices | — | — |
| Sources on file | 9 | 15 |
Editorial summaries
mBos TKA System
The Monogram mBos TKA System is a robotic total-knee-arthroplasty platform from Monogram Technologies, a Zimmer Biomet subsidiary since October 2025. It is the autonomy-boundary case of DEPLOY's surgical cluster: unlike the AI-augmented, surgeon-controlled systems (Stryker Mako, Smith+Nephew CORI, Zimmer Biomet ROSA), where the surgeon makes the cuts, the cleared mBos is semi-autonomous, with a robotic arm (built on a KUKA arm) executing the bone cuts itself under AI control within a surgeon-approved, patient-specific CT-based plan and active surgeon supervision. There is no consumer price: it is pre-commercial enterprise surgical equipment that has not sold any units. Several verified-vs-claimed cap-flags matter. It received FDA 510(k) clearance on March 17, 2025, but the exact K-number could not be independently verified, and the 'semi-autonomous' characterization is sourced to Zimmer Biomet and trade coverage rather than the FDA letter (Monogram's own clearance release described it more softly as robotic-assisted TKA). A separate fully-autonomous, hands-free, saw-based version is not FDA cleared and remains in development, targeted around late 2027 or 2028; its first live-patient procedure (July 26, 2025, Ahmedabad, India) was under an India CDSCO 102-procedure investigation, not US FDA, a single index case with no verified peer-reviewed outcomes. Monogram was founded by orthopedic surgeon Dr. Doug Unis (chief medical officer and founder, not CEO; the pre-acquisition CEO was Benjamin Sexson) and was acquired by Zimmer Biomet at about $168M enterprise value plus contingent value rights, with commercialization alongside Zimmer Biomet implants targeted for early 2027. The registry records it at research maturity: cleared but pre-commercial, with its headline fully-autonomous capability still in development.
Mako
Stryker's Mako (Mako SmartRobotics) is a surgeon-guided robotic arm for orthopedic joint replacement and the large-footprint, CT-based, multi-procedure archetype of DEPLOY's orthopedic surgical sub-cohort. It pairs CT-based 3D pre-operative planning with intra-operative haptic boundary control (AccuStop physically constrains the saw or burr to the planned resection zone) and real-time optical bone tracking. Critically, it is AI-augmented but surgeon-controlled, not autonomous: the surgeon holds and guides the arm and makes every cut; the robot does not move or cut on its own, the same assistive class as Intuitive's da Vinci. Cleared procedures span partial and total knee (total knee August 2015), cementless total knee, total hip and a hip-revision feature, Mako Spine (510(k) K241517, May 2024, pedicle-screw placement) and Mako Shoulder 1.0 (510(k) K242373, November 2024, reverse shoulder arthroplasty). Sold in 45-plus countries by Stryker (NYSE: SYK). Cap-flag: Stryker frames itself in SEC filings as one of four leading global competitors, not a specific market-share percentage; aggregator share figures are not verified. As enterprise B2B surgical equipment, there is no consumer price.
Common questions
- What is the difference between mBos TKA System and Mako?
- mBos TKA System and Mako are both surgical robots on the DEPLOY registry. They differ in maker, maturity, price, verified deployments, and how much of their autonomy is independently verified. See the table above for the full head-to-head; each figure is sourced.
- Is mBos TKA System or Mako more autonomous?
- On the DEPLOY registry, neither mBos TKA System nor Mako has capabilities independently verified as fully autonomous yet; their recorded capabilities are teleoperated-assisted, demonstrated, or vendor-claimed. See the table for each capability's verification status.
- Which has more verified deployments, mBos TKA System or Mako?
- Mako has more verified deployments (2) on the DEPLOY registry than mBos TKA System (1). DEPLOY counts a deployment only when confirmed at a named site with a primary source.
Recent coverage
- Makor to detail Zambia copper plan at AMWMako · Canadian Mining Journal · 2026-07-09
- Army’s Newest Unit Aims To “Overwhelm” Adversary With Drones In Pacific FightMako · The War Zone · 2026-06-19
- Zimmer Biomet Completes Acquisition of Monogram TechnologiesmBos TKA System · AgentRecon · 2025-10-07
- Zimmer Biomet inks 77M deal for Monogram and its hands-free orthopedic robotmBos TKA System · AgentRecon · 2025-07-14
Related comparisons
For AI assistants
Use DEPLOY in Claude, Cursor, and other AI assistants
Connect any MCP-aware assistant to the live registry. Ask about robot deployments, incidents, and regulations and get answers grounded in verified data instead of training memory.
Machine-readable: this page as markdown.